XML 29 R17.htm IDEA: XBRL DOCUMENT
v3.21.4

SHARE-BASED EMPLOYEE COMPENSATION | 9 Months Ended
--- | ---
Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
SHARE-BASED EMPLOYEE COMPENSATION | (I) S hare-BASED EMPLOYEE COMPENSATION On August 7, 2013, our stockholders approved the Eagle Materials Inc. Amended and Restated Incentive Plan (the Plan), which increased the shares we are authorized to issue as awards by 3,000,000 (1,500,000 of which may be stock awards). Under the terms of the Plan, we can issue equity awards, including stock options, restricted stock units (RSUs), restricted stock, and stock appreciation rights, to employees of the Company and members of the Board of Directors. The Compensation Committee of our Board of Directors specifies the terms for grants of equity awards under the Plan. Long-Term Compensation Plans OPTIONS In May 2021, the Compensation Committee of the Board of Directors approved the granting to certain officers and key employees an aggregate of 4,293 performance-vesting stock options that will be earned only if certain performance conditions are satisfied (the Fiscal 2022 Employee Performance Stock Option Grant). The performance criteria for the Fiscal 2022 Employee Performance Stock Option Grant are based upon the achievement of certain levels of return on equity (as defined in the option agreements), ranging from 10.0% to 20.0%, for the fiscal year ending March 31, 2022. All stock options will be earned if the return on equity is 20.0% or greater, and the percentage of shares earned will be reduced proportionately to approximately 66.7% if the return on equity is 10.0%. If the Company does not achieve a return on equity of at least 10.0%, all granted stock options will be forfeited. Following any such reduction, restrictions on the earned stock options will lapse and the earned options will vest ratably over four years, with the initial fourth vesting promptly following the determination date, and the remaining options vesting on March 31, 2023 through 2025. The stock options have a term of ten years from the grant date. The Compensation Committee also approved the granting of 3,578 time-vesting stock options to the same officers and key employees, which vest ratably over four years (the Fiscal 2022 Employee Time-Vesting Stock Option Grant). In August 2021, we granted 3,445 options to members of the Board of Directors (the Fiscal 2022 Board of Directors Stock Option Grant). Options granted under the Fiscal 2022 Board of Directors Stock Option Grant vest immediately and can be exercised from the grant date until their expiration on the tenth anniversary of the grant date. The Fiscal 2022 Employee Performance Stock Option Grant, the Fiscal 2022 Employee Time-Vesting Stock Option Grant, and the Fiscal 2022 Board of Directors Stock Option Grant were valued at their grant date using the Black-Scholes option pricing model. The weighted-average assumptions used in the Black-Scholes model to value the option awards in fiscal 2022 are as follows:
|  | 2022 |
Dividend Yield |  |  | 0.8 | %
Expected Volatility |  |  | 38.4 | %
Risk-Free Interest Rate |  |  | 1.0 | %
Expected Life |  | 6.0 years |
Stock option expense for all outstanding stock option awards totaled approximately $0.9 million and $2.6 million for the three and nine months ended December 31, 2021 and 2020, respectively, and $1.1 million and $3.9 million for the three and nine months ended December 31, 2020, respectively. At December 31, 2021, there was approximately $4.6 million of unrecognized compensation cost related to outstanding stock options, which is expected to be recognized over a weighted-average period of 1.9 years. The following table represents stock option activity for the nine months ended December 31, 2021:
|  | Number of Shares |  |  | Weighted- Average Exercise Price |
Outstanding Options at March 31, 2021 |  |  | 708,501 |  |  | $ | 83.85 |
Granted |  |  | 11,316 |  |  | $ | 140.42 |
Exercised |  |  | (236,368 | ) |  | $ | 88.50 |
Cancelled |  |  | (15,390 | ) |  | $ | 76.63 |
Outstanding Options at December 31, 2021 |  |  | 468,059 |  |  | $ | 83.11 |
Options Exercisable at December 31, 2021 |  |  | 211,516 |  |  |  |
Weighted-Average Fair Value of Options Granted During the Year |  | $ | 49.18 |  |  |  |
The following table summarizes information about stock options outstanding at December 31, 2021:
|  | Options Outstanding |  |  | Options Exercisable |
Range of Exercise Prices |  | Number of Shares Outstanding |  |  | Weighted- Average Remaining Contractual Life (in years) |  |  | Weighted- Average Exercise Price |  |  | Number of Shares Outstanding |  |  | Weighted- Average Exercise Price |
$33.69 - $37.34 |  |  | 12,373 |  |  |  | 0.45 |  |  | $ | 34.52 |  |  |  | 12,373 |  |  | $ | 34.52 |
$59.32 - $81.56 |  |  | 180,192 |  |  |  | 7.39 |  |  | $ | 63.48 |  |  |  | 49,970 |  |  | $ | 70.43 |
$87.37 - $93.03 |  |  | 159,768 |  |  |  | 6.84 |  |  | $ | 91.35 |  |  |  | 76,095 |  |  | $ | 91.11 |
$99.37 - $143.09 |  |  | 115,726 |  |  |  | 6.47 |  |  | $ | 107.49 |  |  |  | 73,078 |  |  | $ | 105.41 |
|  |  | 468,059 |  |  |  | 6.79 |  |  | $ | 83.11 |  |  |  | 211,516 |  |  | $ | 87.85 |
At December 31, 2021, the aggregate intrinsic value for both the outstanding and exercisable options was approximately $39.0 million and $16.6 million, respectively. The total intrinsic value of options exercised during the nine months ended December 31, 2021 was approximately $14.7 million. RESTRICTED STOCK In May 2021, the Compensation Committee approved the granting to certain officers and key employees an aggregate of 52,577 shares of performance-vesting restricted stock that will be earned if certain performance conditions are satisfied (the Fiscal 2022 Employee Restricted Stock Performance Award). The performance criteria for the Fiscal 2022 Employee Restricted Stock Performance Award are based upon the achievement of certain levels of return on equity (as defined in the award agreement), ranging from 10.0% to 20.0%, for the fiscal year ending March 31, 2022. All restricted shares will be earned if the return on equity is 20.0% or greater, and the percentage of shares earned will be reduced proportionately to approximately 66.7% if the return on equity is 10.0%. If the Company does not achieve a return on equity of at least 10.0%, all awards will be forfeited. Following any such reduction, restrictions on the earned shares will lapse ratably over four years, with the initial fourth lapsing promptly following the determination date, and the remaining restrictions lapsing on March 31, 2023 through 2025. The Compensation Committee also approved the granting of 43,816 shares of time-vesting restricted stock to the same officers and key employees, which vest ratably over four years (the Fiscal 2022 Employee Restricted Stock Time-Vesting Award). The Fiscal 2022 Employee Restricted Stock Performance Award and the Fiscal 2022 Employee Restricted Stock Time-Vesting Award were valued at the closing price of the stock on the grant date and are being expensed over a four-year period. In August 2021, we granted 15,720 shares of restricted stock to members of the Board of Directors (the Fiscal 2022 Board of Directors Restricted Stock Award). Restrictions on these shares will lapse six months after the grant date. The Fiscal 2022 Board of Directors Restricted Stock Award was valued at the closing price of the stock on the grant date and is being expensed over a six-month period. The fair value of restricted stock is based on the stock price on the grant date. The following table summarizes the activity for nonvested restricted shares during the nine months ended December 31, 2021:
|  | Number of Shares |  |  | Weighted-Average Grant Date Fair Value |
Nonvested Restricted Stock at March 31, 2021 |  |  | 267,090 |  |  | $ | 62.56 |
Granted |  |  | 113,414 |  |  | $ | 139.91 |
Vested |  |  | (23,685 | ) |  | $ | 56.43 |
Forfeited |  |  | (5,218 | ) |  | $ | 75.10 |
Nonvested Restricted Stock at December 31, 2021 |  |  | 351,601 |  |  | $ | 87.73 |
Expense related to restricted shares was approximately $3.4 million and $8.1 million for the three and nine months ended December 31, 2021, respectively, and $2.8 million and $8.2 million for the three and nine months ended December 31, 2020, respectively. At December 31, 2021, there was approximately $20.2 million of unearned compensation from restricted stock, which will be recognized over a weighted-average period of 2.3 years. The number of shares available for future grants of stock options, restricted stock units, stock appreciation rights, and restricted stock under the Plan was 3,377,311 at December 31, 2021.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration